Fed. Circ. Affirms PTAB Ax Of AbbVie's Humira Patent

By Hannah Albarazi (January 8, 2020, 4:06 PM EST) -- The Federal Circuit on Tuesday summarily affirmed the Patent Trial and Appeal Board's inter partes review decisions invalidating a key patent for AbbVie Biotechnology Ltd.'s top-selling Humira, an immunosuppressant drug that brought in more than $13.6 billion in U.S. sales revenue in 2018....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!